IBDEI0OZ ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11433,0)
 ;;=D86.86^^68^685^39
 ;;^UTILITY(U,$J,358.3,11433,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11433,1,3,0)
 ;;=3^Sarcoid Arthropathy
 ;;^UTILITY(U,$J,358.3,11433,1,4,0)
 ;;=4^D86.86
 ;;^UTILITY(U,$J,358.3,11433,2)
 ;;=^5002451
 ;;^UTILITY(U,$J,358.3,11434,0)
 ;;=D86.87^^68^685^43
 ;;^UTILITY(U,$J,358.3,11434,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11434,1,3,0)
 ;;=3^Sarcoid Myositis
 ;;^UTILITY(U,$J,358.3,11434,1,4,0)
 ;;=4^D86.87
 ;;^UTILITY(U,$J,358.3,11434,2)
 ;;=^5002452
 ;;^UTILITY(U,$J,358.3,11435,0)
 ;;=D86.3^^68^685^49
 ;;^UTILITY(U,$J,358.3,11435,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11435,1,3,0)
 ;;=3^Sarcoidosis of Skin
 ;;^UTILITY(U,$J,358.3,11435,1,4,0)
 ;;=4^D86.3
 ;;^UTILITY(U,$J,358.3,11435,2)
 ;;=^5002445
 ;;^UTILITY(U,$J,358.3,11436,0)
 ;;=D86.81^^68^685^41
 ;;^UTILITY(U,$J,358.3,11436,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11436,1,3,0)
 ;;=3^Sarcoid Meningitis
 ;;^UTILITY(U,$J,358.3,11436,1,4,0)
 ;;=4^D86.81
 ;;^UTILITY(U,$J,358.3,11436,2)
 ;;=^5002446
 ;;^UTILITY(U,$J,358.3,11437,0)
 ;;=D86.82^^68^685^50
 ;;^UTILITY(U,$J,358.3,11437,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11437,1,3,0)
 ;;=3^Sarcoidosis,Multiple Cranial Nerve Palsies
 ;;^UTILITY(U,$J,358.3,11437,1,4,0)
 ;;=4^D86.82
 ;;^UTILITY(U,$J,358.3,11437,2)
 ;;=^5002447
 ;;^UTILITY(U,$J,358.3,11438,0)
 ;;=D86.84^^68^685^44
 ;;^UTILITY(U,$J,358.3,11438,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11438,1,3,0)
 ;;=3^Sarcoid Pyelonephritis
 ;;^UTILITY(U,$J,358.3,11438,1,4,0)
 ;;=4^D86.84
 ;;^UTILITY(U,$J,358.3,11438,2)
 ;;=^5002449
 ;;^UTILITY(U,$J,358.3,11439,0)
 ;;=D86.85^^68^685^42
 ;;^UTILITY(U,$J,358.3,11439,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11439,1,3,0)
 ;;=3^Sarcoid Myocarditis
 ;;^UTILITY(U,$J,358.3,11439,1,4,0)
 ;;=4^D86.85
 ;;^UTILITY(U,$J,358.3,11439,2)
 ;;=^5002450
 ;;^UTILITY(U,$J,358.3,11440,0)
 ;;=D86.83^^68^685^40
 ;;^UTILITY(U,$J,358.3,11440,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11440,1,3,0)
 ;;=3^Sarcoid Iridocyclitis
 ;;^UTILITY(U,$J,358.3,11440,1,4,0)
 ;;=4^D86.83
 ;;^UTILITY(U,$J,358.3,11440,2)
 ;;=^5002448
 ;;^UTILITY(U,$J,358.3,11441,0)
 ;;=D84.1^^68^685^16
 ;;^UTILITY(U,$J,358.3,11441,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11441,1,3,0)
 ;;=3^Defects in Complement System
 ;;^UTILITY(U,$J,358.3,11441,1,4,0)
 ;;=4^D84.1
 ;;^UTILITY(U,$J,358.3,11441,2)
 ;;=^5002439
 ;;^UTILITY(U,$J,358.3,11442,0)
 ;;=D81.810^^68^685^5
 ;;^UTILITY(U,$J,358.3,11442,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11442,1,3,0)
 ;;=3^Biotinidase Deficiency
 ;;^UTILITY(U,$J,358.3,11442,1,4,0)
 ;;=4^D81.810
 ;;^UTILITY(U,$J,358.3,11442,2)
 ;;=^5002422
 ;;^UTILITY(U,$J,358.3,11443,0)
 ;;=E88.01^^68^685^2
 ;;^UTILITY(U,$J,358.3,11443,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11443,1,3,0)
 ;;=3^Apha-1 Antitrypsin Deficiency
 ;;^UTILITY(U,$J,358.3,11443,1,4,0)
 ;;=4^E88.01
 ;;^UTILITY(U,$J,358.3,11443,2)
 ;;=^331442
 ;;^UTILITY(U,$J,358.3,11444,0)
 ;;=J09.X1^^68^685^25
 ;;^UTILITY(U,$J,358.3,11444,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11444,1,3,0)
 ;;=3^Influenza d/t Indent Novel Influenza A Virus w/ Pneumonia
 ;;^UTILITY(U,$J,358.3,11444,1,4,0)
 ;;=4^J09.X1
 ;;^UTILITY(U,$J,358.3,11444,2)
 ;;=^5008144
 ;;^UTILITY(U,$J,358.3,11445,0)
 ;;=J09.X2^^68^685^26
 ;;^UTILITY(U,$J,358.3,11445,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11445,1,3,0)
 ;;=3^Influenza d/t Indent Novel Influenza A Virus w/ Resp Manifest
 ;;^UTILITY(U,$J,358.3,11445,1,4,0)
 ;;=4^J09.X2
 ;;^UTILITY(U,$J,358.3,11445,2)
 ;;=^5008145
 ;;^UTILITY(U,$J,358.3,11446,0)
 ;;=J09.X3^^68^685^27
